SEC Form 4 · accession 0001179110-15-003167
AbbVie Inc. · ABBV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Severino
Officer — EVP, R&D and CSO
Period of report
Feb 19, 2015
Accepted (ET)
Feb 23, 2015 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551152
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.01 par valueF1 | Feb 19, 2015 | A | 52,860 | $0.00 | A | 194,485 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F2 | $58.88 | Feb 19, 2015 | A | 104,480 | A | Feb 19, 2016 | Feb 18, 2025 | Common stock | 104,480 | 104,480 | D |
Explanation of responses
- F1This stock represents performance vested restricted stock under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have a stock withheld for tax purposes.
- F2Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 34,827 on 02/19/2016, 34,826 on 02/19/2017, and 34,826 on 02/19/2018.